证券代码：300298 证券简称： 三诺生物 公告编号：2019-069 三诺生物传感股份有限公司 关于参加2019年湖南辖区上市公司 投资者网上接待日活动的公告 本公司及董事会全体成员保证本公告内容真实、准确、完整，不存在任何 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，三诺生物传感股份有限公司（以下简称 "公司"）将于 2019 年 9 月 10 日（星期二）参加由中国证券监督管理委员会湖南 监管局指导，湖南省上市公司协会与深圳市全景网络有限公司联合举办的"2019 年湖南辖区上市公司投资者网上接待日活动"，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公司提供的互联网 平台举行，投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）或关注微信 公众号：全景财经，参与公司本次投资者网上接待日活动，活动时间为 2019 年 9 月 10 日（星期二）下午 15:00 至 17:00。 届时公司董事会秘书兼财务总监黄安国先生将通过网络在线问答互动的形 式，与投资者就公司治理、发展战略、经营状况等投资者关注的问题进行沟通与 交流。 欢迎广大投资 ...

Market Demand and Expansion - The company reported a significant increase in market demand for blood glucose monitoring products due to rising awareness of diabetes prevention, with a potential market expansion driven by national policies [2]. - The company aims to expand its POCT product sales by establishing a dedicated department and adopting new business models [27]. - The company is committed to international market expansion, particularly in Latin America and the Asia-Pacific region, while enhancing collaboration with partners [41]. - Market expansion efforts are underway, targeting Southeast Asia, with plans to establish distribution partnerships in three new countries by the end of 2019 [48]. Financial Performance - Total revenue for the first half of 2019 was CNY 814,506,766.48, representing a 6.98% increase compared to CNY 761,337,540.44 in the same period of 2018 [18]. - Net profit attributable to shareholders decreased by 22.94% to CNY 129,545,371.12 from CNY 168,102,888.10 year-on-year [18]. - Operating cash flow increased significantly to CNY 208,209,833.91, a 3,531.16% increase from a negative cash flow of CNY -6,068,198.62 in the same period last year [18]. - The company reported a significant increase in revenue, with a year-on-year growth of 25% in the first half of 2019 [48]. - The company set a revenue guidance for the next quarter, projecting a growth of 20% year-on-year, aiming for a total revenue of approximately 500 million RMB [48]. Research and Development - R&D investment for the reporting period was approximately $1.07 million, accounting for 8.39% of total revenue, with 453 R&D personnel, making up 18.68% of total employees [31]. - The company applied for 51 patents during the reporting period, including 19 invention patents and 22 utility model patents, with 17 new patents authorized in China [31]. - The company is investing in R&D for advanced diagnostic technologies, with a budget allocation of 50 million RMB for the upcoming fiscal year [49]. - The company focuses on research and development of blood glucose testing systems, instruments, and test strips, with internal R&D expenditures categorized into research and development phases [190]. Product Development and Innovation - The company has transitioned from a blood glucose monitoring system provider to a provider of chronic disease instant detection (POCT) products and services after acquiring PTS [25]. - New product development includes multi-indicator detection systems and portable multifunctional testing devices, focusing on diabetes and chronic disease management [30]. - The company launched the AGEscan device for non-invasive diabetes risk screening, utilizing clinical big data for risk assessment [43]. - The company has developed a series of enzyme-based test kits for various clinical applications, including kidney function monitoring and heart disease diagnosis [50]. Quality Control and Compliance - The company emphasizes the importance of quality control in its production processes, particularly as it scales up production, to mitigate potential product liability risks [4]. - The company has established a comprehensive quality control system, achieving ISO 13485 and EU CE certifications, and is working towards FDA compliance [32]. - The company implemented strict quality control measures to ensure product safety and stability throughout the production process [45]. - The company is committed to maintaining high standards in product development and regulatory compliance, as evidenced by its active registration processes [52]. Acquisitions and Integration - The company has completed the acquisition of PTS, which has resulted in the recognition of goodwill on its balance sheet, highlighting the importance of effective integration to avoid goodwill impairment risks [6]. - The company is focused on integrating its overseas acquisitions, Trividia and PTS, to achieve synergies and enhance operational efficiency [6]. - There is a risk of goodwill impairment if the integration of PTS does not meet expectations, which could negatively affect the company's financial results [93]. Operational Efficiency - The company is enhancing its production and supply chain efficiency through standardized and automated processes [44]. - The company is optimizing management systems such as OA and CRM, and is implementing a more powerful ERP and MES system to enhance core business process coverage [45]. - The company has established a comprehensive corporate governance structure to support its operational needs and growth strategy [6]. Talent Management - The company acknowledges the risk of talent loss as it expands rapidly, despite having a robust talent management strategy in place [6]. - The company is focusing on the construction of a high-performance talent incentive mechanism to promote leapfrog development through organizational change and performance improvement systems [45]. Shareholder and Financial Structure - The company has not declared any cash dividends or stock bonuses for the reporting period, indicating a focus on reinvestment [2]. - The company’s total share capital increased from 471,095,612 shares to 565,314,734 shares following the 2017 profit distribution plan, which distributed 3.00 CNY per 10 shares and issued 2 additional shares [99]. - The company’s actual controller changed from a joint control by two shareholders to a single control by Mr. Li Shaobo [111]. Risks and Challenges - The company is facing potential risks from intensified industry competition and the need for ongoing technological advancements to sustain its market position [5]. - The company faces risks from intensified industry competition, with potential impacts on operational performance if it fails to enhance its technological and management capabilities [87]. - The company is committed to improving quality control to mitigate product liability risks associated with its diabetes monitoring products [89].

三诺生物传感股份有限公司 2018 年年度报告全文 1 三诺生物传感股份有限公司 2018 年年度报告 2019 年 03 月 1 三诺生物传感股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 2 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人李少波、主管会计工作负责人黄安国及会计机构负责人(会计主 管人员)何竹子声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险 认识，并且应当理解计划、预测与承诺之间的差异。本公司请投资者认真阅读 本年度报告全文，并特别注意下列风险因素： （1）行业竞争加剧的风险 公司所处的 POCT 监测产品产业应用领域前景广阔，受益于国家政策和不断 扩大的市场需求，未来将吸引更多国内外厂商进入该行业，公司将面对更为激 烈市场竞争。公司在行业内具有一定的技术、成本、品牌等综合优势 ...

Financial Performance - Total revenue for Q1 2019 was CNY 369,898,285.23, representing an increase of 18.03% compared to CNY 313,404,662.60 in the same period last year[3]. - Net profit attributable to shareholders decreased by 41.15% to CNY 49,012,855.08 from CNY 83,289,359.48 year-on-year[3]. - Net profit excluding non-recurring gains and losses was CNY 45,599,863.52, down 21.04% from CNY 57,749,097.89 in the previous year[3]. - Basic and diluted earnings per share were both CNY 0.0867, a decrease of 44.99% from CNY 0.1576 in the previous year[3]. - Operating profit fell by 38.73% to CNY 56,341,244.98, reflecting the overall performance decline[10]. - The total profit for the period was ¥59,439,958.51, a decrease of 36.19% year-on-year, primarily due to the absence of government subsidies received in the previous year[16]. - The total comprehensive income for the period was CNY 28,548,916.48, compared to CNY 76,881,075.19 in the same quarter last year[38]. - The total profit for the period was CNY 59,093,629.36, compared to CNY 79,657,468.91 in the same quarter last year, showing a decrease of 25.8%[39]. Cash Flow - Net cash flow from operating activities surged to CNY 48,582,209.94, a significant increase of 16,345.64% compared to CNY 295,410.80 in the same period last year[3]. - Cash flow from operating activities increased by 16345.64% to CNY 48,582,209.94, driven by higher customer payments[11]. - The net increase in cash and cash equivalents was -¥117,451,462.84, a decline of 123.82% compared to the previous year, mainly due to increased payments for construction projects[14]. - The ending balance of cash and cash equivalents was ¥539,614,012.63, down 41.93% from the previous year[14]. - The net cash flow from operating activities for the first quarter was ¥56,297,189.33, an increase from ¥19,419,851.94 in the previous year, representing a growth of approximately 189%[43]. - The net cash flow from investment activities was -¥104,935,894.10, a significant improvement from -¥479,870,856.09 in the previous year[43]. - The cash flow from operating activities was positively impacted by a reduction in cash payments to employees, which totaled ¥75,124,750.54, compared to ¥67,049,516.93 in the previous year[43]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,100,843,786.66, reflecting a growth of 3.36% from CNY 3,000,007,971.94 at the end of the previous year[3]. - Total liabilities increased significantly, with long-term borrowings rising due to new project financing[8]. - Total liabilities rose to CNY 447,750,804.58 compared to CNY 377,011,731.08 at the end of 2018[33]. - The company's current assets decreased to CNY 1,267,958,806.99 from CNY 1,303,136,236.63 in the previous period[31]. - Total current assets as of March 31, 2019, amounted to ¥703,742,819.58, an increase from ¥681,516,100.24 at the end of 2018[34]. - The company's total liabilities and shareholders' equity combined amounted to CNY 3,000,007,971.94[46]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,609[5]. - The largest shareholder, Li Shaobo, held 26.77% of the shares, totaling 151,362,062 shares[5]. - Net assets attributable to shareholders increased by 1.15% to CNY 2,653,092,982.08 from CNY 2,622,996,240.86 at the end of the previous year[3]. Research and Development - The company plans to enhance its R&D investment and accumulate product and technology reserves to improve market competitiveness[19]. - Research and development expenses for Q1 2019 were ¥31,341,879.14, an increase of 21.06% compared to ¥25,809,981.41 in Q1 2018[37]. - Research and development expenses increased to CNY 21,568,767.00, up from CNY 17,911,796.46 in the previous year, reflecting a focus on innovation[39]. Market Strategy - The company aims to expand its market share in the grassroots medical sector by promoting its multi-parameter detection systems[16]. - The company is focusing on international market expansion, particularly in the Asia-Pacific region, to enhance its market presence[17]. - The company aims to continuously develop new products to ensure rapid growth in the high-tech POCT testing instrument industry, which faces intense competition and technological risks[21]. Governance and Management - The company has established a comprehensive governance structure and talent reserve to support its rapid expansion, but management risks may arise if resources are not effectively utilized[22]. - The company plans to enhance its management and operational systems, including performance improvement and talent strategy management, to match its growth[23]. - The integration of overseas acquisition targets is crucial, and the company will establish collaborative mechanisms with Trividia and PTS to achieve synergy in operations and product development[24]. - There is a risk of goodwill impairment if the integration with PTS does not yield expected results, which could negatively impact the company's financial performance[24].

Market Demand and Competition - The company reported a significant increase in market demand for POCT monitoring products, benefiting from national policies, but faces intensified competition from both domestic and international manufacturers[2]. - The company faces potential risks from intensified competition in the slow disease monitoring sector, necessitating continuous improvement in technology and management[2]. - The company has outlined a strategic focus on expanding its market presence while navigating the challenges posed by new technologies and competitive pressures[3]. - The company aims to expand its market presence in Southeast Asia, targeting a 10% market share by 2021[18]. - The company is focusing on international market expansion, particularly in Latin America and South Asia, while deepening cooperation with TISA[51]. Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2018, representing a year-on-year increase of 15% compared to 2017[18]. - The net profit attributable to shareholders was RMB 300 million, reflecting a growth of 20% from the previous year[18]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[58]. - The company has set a revenue target of RMB 1.5 billion for 2019, representing a growth of 25% year-on-year[18]. - The company aims to achieve a revenue target of RMB 1.78 billion for the year 2019, focusing on steady growth in sales and operating profit[112]. Research and Development - Continuous investment in R&D is crucial for the company to maintain its competitive edge in the rapidly evolving slow disease monitoring industry, with a focus on new product development and technological innovation[3]. - The company is committed to enhancing its R&D capabilities by attracting high-quality talent to support ongoing innovation and market expansion[3]. - The company emphasized continuous R&D investment, focusing on high-tech, multi-parameter detection systems for diabetes and chronic disease management[36]. - The company increased R&D investment to ¥160.52 million, accounting for 10.35% of total revenue, with 444 R&D personnel representing 19.06% of total employees[37]. - The company plans to continue pursuing corporate social responsibility alongside business development, contributing to social harmony and stability[179]. Acquisitions and Integration - The company has completed the acquisition of PTS, resulting in the recognition of goodwill on its balance sheet, which poses a risk of impairment if the integration does not meet expectations[6]. - The company is integrating its overseas acquisitions, Trividia and PTS, which may face challenges due to differences in management practices and corporate culture[4]. - The company acknowledges the risk of not being able to effectively integrate acquired companies, which could adversely affect profitability and shareholder interests[6]. - The company has recognized goodwill on its balance sheet following the acquisition of PTS, which poses a risk of impairment if effective integration and synergy are not achieved[120]. - The company has expanded its subsidiary, Sannuo Health Management, to become a wholly-owned subsidiary after completing the acquisition[184]. Product Development and Quality Control - The company emphasizes the importance of product quality control, particularly as production scales up, to mitigate potential risks related to product liability and quality issues[3]. - The company has established a comprehensive quality control system in accordance with ISO:13485:2016 and FDA requirements, ensuring product safety and quality[38]. - The company is enhancing its management and talent incentive mechanisms to improve operational efficiency and employee engagement[43]. - The company is implementing standardized production processes to improve production efficiency and product quality[54]. - The company has launched one new registered medical device product during the reporting period, maintaining a total of 37 valid medical device registrations[55]. Shareholder and Financial Policies - A cash dividend of 3.00 RMB per 10 shares (including tax) has been proposed, based on a total of 565,314,734 shares[6]. - The cash dividend policy is compliant with the company's articles of association and has undergone proper decision-making procedures[125]. - The company has maintained a consistent cash dividend payout, with the cash dividends over the past three years being 169,594,420.20 RMB in 2018, 141,328,683.60 RMB in 2017, and 121,807,955.52 RMB in 2016[127]. - The company’s profit distribution policy has been strictly followed, ensuring that all shareholders, especially minority shareholders, have their interests protected[125]. - The company has committed to reducing and regulating related party transactions, ensuring fair pricing and compliance with relevant laws and regulations[132]. Strategic Partnerships and Collaborations - The company established a long-term strategic partnership with TISA in Cuba to expand into the South American market through OEM[29]. - The company is actively exploring collaborative procurement with PTS and Trividia to improve raw material quality and reduce product costs[28]. - The company aims to leverage its partnerships with Trividia and PTS to enhance product development and market reach, particularly in the diabetes management sector[112]. - The company plans to establish a collaborative working mechanism with Trividia and PTS to enhance operational management, product development, production, and international market expansion[120]. - The company is pursuing both internal innovation and external acquisitions to secure leading technologies and enhance brand influence[117]. Operational Efficiency and Management - The company recognizes the challenge of adapting management and human resources to its rapid expansion and is focused on optimizing its operational management systems[119]. - The company is committed to improving management levels and expanding market areas while fostering a strong technical team[111]. - The company has implemented a customer feedback control program to monitor and improve customer satisfaction[38]. - The company is enhancing its digital health platform, integrating AI capabilities to provide personalized health insights for users[56]. - The company is enhancing its brand promotion efforts through online and offline activities to increase product awareness[51].

Financial Performance - Net profit attributable to shareholders decreased by 39.91% to CNY 69,877,849.80 for the reporting period[7] - Basic earnings per share decreased by 45.09% to CNY 0.1309 for the reporting period[7] - The weighted average return on net assets decreased by 6.19 percentage points to 2.90%[7] - The net profit attributable to the parent company decreased by 938,000 yuan, a decline of 45.57% compared to the same period last year[20] - The company reported a comprehensive income total of CNY 91,404,024.05, compared to CNY 105,567,357.29 in the previous year[45] - The net profit for the third quarter was CNY 215.76 million, slightly down from CNY 216.52 million year-over-year, indicating a decrease of 0.35%[56] - The operating profit for the quarter was CNY 241.86 million, compared to CNY 253.98 million in the previous year, reflecting a decline of 4.8%[56] Revenue and Operating Costs - Operating revenue for the reporting period was CNY 396,865,311.27, representing a 47.23% increase year-on-year[7] - Operating revenue increased by CNY 395.56 million, a growth of 51.87%, mainly due to increased revenue from the parent company and the consolidation of Sanofi Health Management Co., Ltd.[19] - Total operating revenue for the third quarter reached CNY 396,865,311.27, a significant increase from CNY 269,563,182.92 in the previous period[42] - Operating costs amounted to CNY 340,634,905.10, compared to CNY 192,668,377.06 in the same period last year, indicating a rise in expenses[42] - Total operating revenue for the period reached CNY 1,158,202,851.71, a significant increase from CNY 762,640,451.98 in the previous period, representing a growth of approximately 52%[51] - Total operating costs increased to CNY 959,539,259.28 from CNY 551,511,611.47, indicating a rise of about 74%[51] Assets and Liabilities - Total assets increased by 79.75% to CNY 2,988,906,758.60 compared to the end of the previous year[7] - Total assets increased by CNY 1.33 billion, a growth of 79.75%, primarily due to the consolidation of Sanofi Health Management Co., Ltd.[18] - Total liabilities increased by CNY 166.09 million, a growth of 60.80%, primarily due to the consolidation of Sanofi Health Management Co., Ltd.[18] - The total liabilities amounted to CNY 439,270,436.45, up from CNY 273,182,225.41, which is an increase of about 60.8%[37] - The company's equity attributable to shareholders reached CNY 2,549,636,322.15, compared to CNY 1,389,593,624.07 at the beginning of the period, indicating a growth of approximately 83.5%[37] Cash Flow - The net cash flow from operating activities decreased by 49.16% to CNY 132,110,816.29 year-to-date[7] - Cash received from sales of goods and services increased by 277,553,200 yuan, a growth of 35.39% year-on-year, mainly due to the inclusion of Sanofi Health Management Co., Ltd. in the consolidated financial statements[21] - Cash outflow from operating activities increased by 367,722,500 yuan, an increase of 58.37% year-on-year, primarily due to increased payments for employee compensation and marketing expenses[22] - Cash flow from investing activities increased by 239,950,100 yuan, an increase of 79.18% year-on-year, primarily due to cash inflows from investment activities[22] - Cash flow from financing activities increased by 538,193,800 yuan, an increase of 5068.97% year-on-year, mainly due to funds raised from the acquisition of Sanofi Health Management Co., Ltd.[23] - The net increase in cash and cash equivalents was 542,829,300 yuan, an increase of 983.58% year-on-year, mainly due to the acquisition of Sanofi Health Management Co., Ltd. and the increase in matured financial products[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,204[11] - The largest shareholder, Li Shaobo, holds 26.77% of the shares, amounting to 151,362,062 shares[11] - The company did not conduct any repurchase transactions among the top shareholders during the reporting period[12] - The company's cash dividend policy was strictly implemented according to the articles of association, ensuring clear standards and ratios for profit distribution, benefiting all shareholders[28] Research and Development - Research and development expenses rose by CNY 49.02 million, an increase of 99.70%, primarily due to higher material inputs and personnel costs[19] - Research and development expenses for the quarter were CNY 33,734,878.42, up from CNY 18,885,452.07 in the previous year, reflecting a focus on innovation[42] - Research and development expenses rose to CNY 98,181,152.09, compared to CNY 49,165,349.09 in the previous period, showing an increase of approximately 100%[51] Other Comprehensive Income - Other comprehensive income after tax increased by 60,621,200 yuan, an increase of 279.68% year-on-year, mainly due to the inclusion of Sanofi Health Management Co., Ltd. in the consolidated financial statements[20] - The total comprehensive income increased by 88,770,600 yuan, an increase of 47.18% year-on-year, primarily due to the increase in net profit and other comprehensive income after tax[20] - The total comprehensive income for the period was CNY 276,926,967.58, compared to CNY 188,156,349.18 in the previous period, representing a growth of about 47%[53] Investment Activities - The company acquired a 14.742% stake in Shenzhen Xinnuo Health Industry Investment Co., Ltd., increasing its ownership from 25% to 39.742%[24] - The company recognized investment income of CNY 23,143,248.48 from the revaluation of its stake in a subsidiary[8] - Investment income for the period was CNY 13,388,424.07, a recovery from a loss of CNY 1,333,438.68 in the previous period[51]

Financial Performance - Total revenue for the reporting period reached ¥761,337,540.44, an increase of 54.41% compared to ¥493,077,269.06 in the same period last year[23]. - Net profit attributable to shareholders was ¥168,102,888.10, up 79.65% from ¥93,572,127.04 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥136,297,821.71, reflecting a 58.19% increase from ¥86,158,374.54 in the previous year[23]. - The company reported a basic earnings per share of ¥0.3073, a 37.68% increase from ¥0.2232 in the same period last year[23]. - Operating profit and total profit were 188.20 million yuan and 196.14 million yuan, respectively, both showing an increase of approximately 67.89% compared to the previous year[45]. - The company achieved a revenue of 761.34 million yuan in the first half of 2018, representing a year-on-year growth of 54.41%[45]. - The company reported a significant increase in revenue, with a year-on-year growth of 25% in the first half of 2018[52]. - The company reported a total revenue of 17.42 million, with a significant increase in user data and engagement metrics[179]. Cash Flow and Investments - The company reported a net cash flow from operating activities of -¥6,068,198.62, a decrease of 103.39% compared to ¥179,211,961.12 in the previous year[23]. - The net cash flow from investing activities increased by 242.00% to ¥186,971,501.95, attributed to an increase in matured financial products compared to the previous year[56]. - The net cash flow from financing activities surged by 493.72% to ¥513,664,682.35, mainly due to significant asset restructuring and fundraising activities[56]. - The company reported a net increase in cash and cash equivalents of ¥699,988,509.50, a 14,305.23% increase, influenced by fundraising from major asset restructuring and the consolidation of Sanofi Health Management[58]. - The company raised RMB 485,911,986.55 through a private placement of 27,987,193 shares to fund chronic disease health management monitoring product capacity expansion and smart health projects[125]. Market Expansion and Strategy - The company has established subsidiaries in various regions, including Hong Kong and India, to expand its market presence[15]. - The company is focusing on expanding its international market presence, particularly in Latin America and the Asia-Pacific region, through collaborations with Trividia and PTS[46]. - The company plans to enhance its clinical market sales and expand its blood glucose management systems in hospitals[33]. - The company is exploring potential acquisitions to enhance its product portfolio, focusing on companies with complementary technologies in the healthcare sector[53]. - The company is committed to enhancing its employee stock ownership plan to align employee interests with company performance[106]. Research and Development - R&D investment amounted to CNY 56.78 million, accounting for 7.46% of total revenue, reflecting the company's commitment to innovation[38]. - The company applied for 16 patents during the reporting period, including 7 invention patents and 9 utility model patents[38]. - The company is investing in R&D for advanced diabetes management technologies, with a budget allocation of 50 million yuan for the next fiscal year[53]. - The company is committed to continuous innovation in diabetes management solutions, including the development of cloud-based management systems and portable testing devices[46]. - The company is focused on enhancing its research and development capabilities to innovate new technologies[179]. Quality Control and Compliance - Quality control remains a critical focus as the company expands production, with potential risks associated with product liability and legal claims[8]. - The company emphasizes the importance of quality control and has implemented a comprehensive internal quality audit system to mitigate potential product liability risks[88]. - The company is enhancing quality control systems, including FDA internal audits and improved traceability systems to increase product quality inspection pass rates[48]. - The company's products are classified as Class II medical devices, ensuring compliance with regulatory standards for safety and efficacy[10]. Acquisitions and Partnerships - The company completed the acquisition of PTS in January 2018, transitioning from a blood glucose monitoring system provider to a provider of POCT products for chronic disease detection[30]. - The acquisition of 64.98% of Sanofi Health Management resulted in an increase in goodwill by CNY 466.43 million, a growth of 3664.12%[35]. - The company established a long-term strategic partnership with TISA in Cuba to expand its overseas market presence[33]. - The company completed a strategic acquisition of a smaller tech firm for $1.5 billion to enhance its product offerings[184]. Shareholder Returns and Dividends - The company reported a plan not to distribute cash dividends or issue bonus shares for the current period[5]. - The board has approved a dividend payout of 0.50 per share, reflecting a commitment to returning value to shareholders[195]. User Engagement and Market Trends - User data indicates that the number of active users for the blood glucose monitoring products reached 1 million, reflecting a 15% increase compared to the previous year[53]. - The focus on early diagnosis and monitoring of diabetes-related conditions aligns with global health trends, potentially driving future revenue growth[10]. - The company is implementing a "Diabetes Patient Discovery Plan" to enhance user engagement and improve service quality for its members[46]. Financial Position and Assets - Total assets at the end of the reporting period were ¥3,036,550,908.04, representing an 82.62% increase from ¥1,662,775,841.45 at the end of the previous year[23]. - The company’s total assets increased due to the capital increase and acquisition, reflecting a strategic expansion in health management services[126]. - The company's equity attributable to shareholders increased to CNY 2,453,381,156.40 from CNY 1,389,593,624.07, representing an increase of approximately 76.7%[158].

Financial Performance - The company's revenue for 2017 reached ¥1,033,007,660.36, representing a 29.80% increase compared to ¥795,841,252.69 in 2016[23]. - Net profit attributable to shareholders was ¥257,971,916.00, a significant increase of 123.94% from ¥115,198,311.32 in the previous year[23]. - The net cash flow from operating activities was ¥243,891,125.99, up by 19.90% from ¥203,417,116.04 in 2016[23]. - The company achieved a basic earnings per share of ¥0.6346, which is a 123.84% increase compared to ¥0.2835 in 2016[23]. - Total assets at the end of 2017 were ¥1,662,775,841.45, reflecting a 12.84% increase from ¥1,473,510,123.64 at the end of 2016[23]. - The weighted average return on equity increased to 19.43% in 2017 from 9.47% in 2016[23]. - The company reported a total of ¥14,027,538.32 in non-recurring gains and losses for 2017, compared to ¥11,342,171.29 in 2016[29]. - The company reported a significant increase in construction in progress, rising by CNY 65.42 million, a growth of 682.99% due to investments in the automation building[35]. - Cash and cash equivalents increased by CNY 107.65 million, a growth of 49.89%, primarily due to a reduction in equity investments during the reporting period[35]. - The company achieved operating revenue of 1,033.01 million CNY in 2017, representing a year-on-year growth of 29.80%[44]. - Operating profit and total profit were 297.43 million CNY and 305.13 million CNY, respectively, with increases of 308.70% and 123.84% compared to the previous year[44]. Research and Development - The company has made significant investments in R&D to strengthen its new product development and innovation capabilities, aiming to capture new market opportunities[8]. - The company’s R&D investment reached CNY 73.98 million, accounting for 7.16% of total revenue, indicating a strong commitment to innovation[38]. - The company has applied for 35 patents during the reporting period, including 10 invention patents, demonstrating its focus on innovation and intellectual property[38]. - The company is investing in R&D for advanced diabetes management technologies, with a budget allocation of 100 million RMB for the upcoming year[52]. - The focus on research and development is evident with multiple new product registrations aimed at enhancing diabetes management solutions[1]. - The company plans to accelerate the R&D and registration of POCT products related to diabetes, cardiovascular diseases, and infectious diseases, focusing on innovative and systematic smart medical solutions[91]. Product Development and Innovation - The company has developed a blood glucose monitoring system with data transmission capabilities and a diabetes management information system, enhancing its product offerings[37]. - The company expanded its product offerings from single blood glucose monitoring to multi-parameter testing systems for diabetes and related chronic diseases[31]. - The company aims to integrate hardware, software, and services for chronic disease management, improving the quality of life for patients with diabetes[32]. - The company has developed a range of glucose monitoring products, including smart glucose meters and test strips, which are primarily used for monitoring blood glucose levels in diabetic patients[1]. - New product registrations include a portable biochemical analyzer and an immunofluorescence analyzer, which were approved in 2017 and 2022 respectively[1]. - The company launched 13 new registered products and held a total of 36 valid medical device registrations by the end of 2017[49]. - The company is focused on enhancing its retail market presence through initiatives like the diabetes patient discovery plan and improving customer service capabilities[44]. - The company is committed to continuous innovation, developing smart health products with data transmission capabilities and establishing a diabetes management service system[47]. Market Expansion and Competition - The company is facing intensified competition in the POCT monitoring product industry, which may impact its operational performance if it fails to enhance its technological and management capabilities[5]. - The company is focusing on expanding its POCT (Point of Care Testing) business to provide comprehensive solutions for chronic disease prevention and treatment[31]. - The company is expanding its international market presence, particularly in Latin America and the Asia-Pacific region, while deepening collaborations with partners like TISA and Trividia[45]. - The company aims to enhance its market position in blood glucose monitoring products and expand its international market share, leveraging its technological and pricing advantages[91]. - The company is actively pursuing market expansion strategies, targeting Southeast Asia and Europe for new market entries in the coming year[189]. Corporate Governance and Shareholder Relations - The company’s financial report is guaranteed to be true, accurate, and complete by its board and management, ensuring accountability for any misrepresentation[4]. - The independent directors played a significant role in the profit distribution decision-making process, ensuring compliance with regulations and protecting minority shareholders' interests[110]. - The profit distribution plan was approved by the board and shareholders, adhering to the company's articles of association and regulatory requirements[110]. - The company has maintained a consistent cash dividend policy, with a minimum of 20% of profits allocated for distribution during growth phases[112]. - The company guarantees not to utilize its controlling shareholder status to harm the interests of the company and minority shareholders[118]. - The company emphasizes shareholder rights protection and adheres to legal regulations for fair information disclosure[147]. Quality Control and Risk Management - The company emphasizes the importance of product quality control, especially as production scales up, to mitigate potential product liability risks[7]. - The company recognizes the potential risks associated with product quality and the need for ongoing vigilance as it expands production[7]. - The company is focused on improving its quality control systems to mitigate potential product liability risks associated with increased production volume[104]. - The company acknowledges the risk of not accurately grasping industry trends, which could hinder its ability to adjust product directions and meet market demands[8]. - The company is aware of the risks related to new product development and technological substitution, emphasizing the need for accurate market trend analysis and timely adjustments in product direction[104]. Employee and Management Structure - The total number of employees in the company is 1,855, with 878 in sales, 503 in production, and 335 in technical roles[199]. - The company paid a total of 2.8518 million yuan in compensation to 13 directors and senior management in 2017[195]. - The company has a diverse educational background among its employees, with 567 holding bachelor's degrees and 568 holding associate degrees[200]. - The company’s management structure includes a mix of experienced professionals from various sectors, enhancing its operational capabilities[197]. - The board of directors and senior management compensation is determined based on the company's profitability and individual performance[195]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, adhering to ISO:13485-2016 production system certification and relevant environmental regulations[151]. - No pollution incidents or disputes occurred during the reporting period, and the company complied with various environmental protection laws[153].

Financial Performance - Total revenue for Q1 2018 reached ¥313,404,662.60, an increase of 33.96% compared to ¥233,954,156.20 in the same period last year[8] - Net profit attributable to shareholders was ¥83,289,359.48, representing an 85.39% increase from ¥44,925,536.46 year-on-year[8] - Basic earnings per share rose to ¥0.1891, up 70.98% from ¥0.1106 in the previous year[8] - The total profit reached ¥93,156,139.13, an increase of 69.42% compared to the previous year[30] - The company reported a total comprehensive income of CNY 76,881,075.19, compared to CNY 43,609,501.17 in the previous period, representing a growth of about 76.3%[61] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,843,629,941.06, a 71.02% increase from ¥1,662,775,841.45 at the end of the previous year[8] - Total assets increased significantly, with intangible assets rising by 77.00 million yuan, a growth of 186.65% due to the consolidation of Sanofi Health[25] - Total liabilities increased to CNY 360,940,365.00 from CNY 273,182,225.41, marking a rise of about 32.2%[52] - The company's total equity rose to CNY 2,495,395,263.00 from CNY 1,420,363,619.71, marking an increase of approximately 75.6%[57] Cash Flow - The company reported a net cash flow from operating activities of ¥295,410.80, a significant decrease of 99.66% compared to ¥86,262,575.42 in the same period last year[8] - Cash flow from operating activities generated a net amount of CNY 295,410.80, a significant decrease from CNY 86,262,575.42 in the previous year[67] - The company reported a net increase in cash and cash equivalents of 528.24 million yuan, a growth of 1,505.11%, mainly from fundraising related to the acquisition of Sanofi Health[28] - Cash and cash equivalents at the end of the reporting period reached CNY 929,216,388.58, up from CNY 323,441,788.60 at the beginning of the period[50] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,298[17] - The largest shareholder, Li Shaobo, holds 26.77% of shares, totaling 126,135,052 shares, with 94,601,289 shares pledged[18] - The second largest shareholder, Che Hongli, holds 21.90% of shares, totaling 103,172,452 shares, with no shares pledged[18] - The company maintains a consistent shareholder agreement between the largest shareholders to ensure stable development[19] Strategic Plans and Market Position - The company plans to enhance R&D investment and product quality control to mitigate potential risks associated with product quality and market competition[14] - The company aims to strengthen its integration strategy for overseas acquisitions, specifically for Trividia and PTS, to achieve expected synergies[13] - The company is focused on expanding its market presence and enhancing its competitive edge through continuous innovation and strategic partnerships[14] - The company plans to enhance its market position by strengthening brand promotion and expanding retail channels[31] Acquisitions and Investments - The company acquired 64.98% of Sanofi Health, resulting in goodwill increasing by 466.43 million yuan, a staggering growth of 3,664.12%[25] - The company has completed the acquisition of 100% equity in Changsha San Nuo Health Management Co., Ltd. through a share issuance[37] - The company raised up to ¥50,265 million through a private placement to support the acquisition[36] Operational Metrics - Operating revenue reached 313.38 million yuan, an increase of 33.95% year-on-year, primarily driven by the consolidation of Sanofi Health's revenue[28] - Sales expenses increased by 28.33 million yuan, a rise of 48.21%, attributed to enhanced marketing efforts for new products[26] - The top five customers' sales included F Company at ¥13,475,261.54, down from ¥18,164,261.72 from the previous year[30] Market Expansion - The company is actively exploring new market opportunities in Latin America and the U.S. for its products[32] - The company plans to continue strengthening channel advantages and enhancing brand promotion to improve sales structure and market penetration[28] Miscellaneous - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[19] - There were no significant changes in the feasibility of investment projects during the reporting period[46] - The first quarter report was not audited[73]

Financial Performance - Operating revenue for the period reached CNY 269,563,182.92, representing a year-on-year growth of 22.36%[7] - Net profit attributable to shareholders increased by 74.50% to CNY 116,285,477.53 for the period[7] - Basic earnings per share rose by 45.25% to CNY 0.2860[7] - The weighted average return on net assets improved to 9.09%, an increase of 3.51% compared to the previous year[7] - The net cash flow from operating activities for the year-to-date reached CNY 259,875,177.75, up 34.52%[7] - The total operating revenue for the third quarter was CNY 269,563,182.92, an increase of 22.3% compared to CNY 220,310,396.35 in the same period last year[42] - The net profit attributable to the parent company was CNY 116,285,477.53, up 74.7% from CNY 66,449,387.09 in the previous year[43] - The total operating revenue for the period reached CNY 762.64 million, a 35.1% increase from CNY 564.57 million in the previous period[49] - The net profit for the period was CNY 209.83 million, up 77.2% from CNY 118.45 million in the same period last year[51] - The operating profit increased to CNY 247.31 million, compared to CNY 86.02 million in the previous period, reflecting a significant growth[51] - The total comprehensive income for the period was CNY 188.16 million, compared to CNY 118.45 million in the previous period, showing strong overall performance[52] Assets and Liabilities - Total assets increased by 5.67% to CNY 1,557,070,339.57 compared to the end of the previous year[7] - The total assets at the end of the period amounted to CNY 1,576,344,064.22, compared to CNY 1,479,710,678.41 at the beginning of the year, reflecting a growth of 6.5%[40] - The company reported a total current liability of CNY 198,475,897.14, up from CNY 185,444,656.50, indicating an increase of approximately 7.0%[36] - The total liabilities increased to CNY 220,789,846.05 from CNY 192,959,669.21, marking a rise of 14.4%[40] - The company's equity increased to CNY 1,333,802,411.42 from CNY 1,277,830,121.51, showing a growth of about 4.4%[36] Cash Flow and Investments - Cash and cash equivalents decreased by 115.19 million yuan, a decline of 53.38%, mainly due to cash dividends and the purchase of financial products[16] - Cash received from sales of goods and services increased by 171.30 million yuan, a rise of 27.94%, attributed to increased sales and corresponding collections[19] - The cash flow from operating activities generated a net amount of CNY 259.88 million, up from CNY 193.19 million year-over-year, reflecting a growth of 34.4%[58] - The cash inflow from investment activities totaled CNY 303.05 million, a decrease from CNY 792.71 million in the previous year[59] - The cash outflow from investment activities was CNY 506.23 million, down from CNY 1,065.58 million year-over-year[59] - The net cash flow from financing activities was negative CNY 111.34 million, compared to negative CNY 100.05 million in the same period last year[61] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,209[10] - The top shareholder, Li Shaobo, holds 30.97% of the shares, amounting to 126,135,052 shares[10] Government and Other Income - The company received government subsidies amounting to CNY 5,854,990.47 during the reporting period[8] - Non-recurring gains and losses totaled CNY 10,556,931.37 for the year-to-date[8] - Other income amounted to CNY 37.52 million, contributing positively to the overall financial performance[51] Tax and Expenses - The company’s tax expenses increased by 29.42 million yuan, a rise of 216.15%, primarily due to an increase in taxable income[18] - The company incurred a tax expense of CNY 43.03 million, which is significantly higher than CNY 13.61 million in the previous period, reflecting increased profitability[51] Strategic Initiatives - The company is in the process of a major asset restructuring, planning to acquire 64.98% equity of Changsha Sanofi Health Management Co., Ltd.[21] - The company plans to introduce PTS's products and technology to the Chinese market, enhancing R&D efficiency and product performance through integration in R&D, procurement, production, and sales[26] - The company is expanding its product line to include instant testing products for chronic diseases, aiming for a broader market reach[26] - The company is focused on enhancing its sales and user service network, particularly in developed and emerging markets, including countries along the "Belt and Road" initiative[26] Other Financial Metrics - Financial expenses rose by 5.15 million yuan, an increase of 138.96%, mainly due to a decrease in time deposit principal and increased exchange losses[18] - The company’s investment income increased by 30.63 million yuan, a growth of 95.83%, due to improved operations of joint ventures and recovery of previously impaired receivables[18] - The investment income for the quarter was CNY 20,825,431.05, compared to a loss of CNY 13,481,579.67 in the same period last year[43] - The investment income reported a loss of CNY 1.33 million, an improvement from a loss of CNY 31.97 million in the previous period[54]